Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden.
Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S49-55. doi: 10.2215/CJN.02720409.
Because inflammation by now is a "traditional" finding that predicts poor outcome and cardiovascular events in the vast majority of patients with ESRD, it could be argued that inflammatory biomarkers should not longer be considered "novel" risk factors. In this review, we forward the hypothesis that, in addition to putative direct proatherogenic effects, persistent inflammation may serve as a catalyst and, in the toxic uremic milieu, modulate the effects of other concurrent vascular and nutritional risk factors. We discuss some recent observational studies, suggesting that the presence of persistent inflammation magnifies the risk for poor outcome via mechanisms related to self-enhancement of the inflammatory cascade and exacerbation of both the wasting and the vascular calcification processes. Because persistent inflammation may be the silent culprit of other commonly observed pathophysiologic alterations in chronic kidney disease, it is imperative that inflammatory markers be regularly monitored and therapeutic attempts be made to target persistent low-grade inflammation in this patient group.
由于炎症目前是一个“传统”的发现,它可以预测绝大多数 ESRD 患者的不良预后和心血管事件,因此可以说炎症生物标志物不应再被视为“新”的危险因素。在这篇综述中,我们提出了一个假设,即除了潜在的直接促动脉粥样硬化作用外,持续性炎症可能作为催化剂,并在有毒的尿毒症环境中,调节其他同时存在的血管和营养危险因素的作用。我们讨论了一些最近的观察性研究,表明持续性炎症通过与炎症级联的自我增强相关的机制以及加剧消耗和血管钙化过程,放大了不良预后的风险。由于持续性炎症可能是慢性肾脏病中其他常见观察到的病理生理改变的沉默罪魁祸首,因此必须定期监测炎症标志物,并尝试针对该患者群体的持续性低度炎症进行治疗。